Life

Briefing: NIH Faces $5 Billion Cut in Trump's 2027 Budget Proposal

Strategic angle: Congress is expected to resist the proposed reduction in funding for the National Institutes of Health.

Briefing: White House Proposes 12% Cut to Federal Health Agencies in 2027 Budget Request

Strategic angle: The proposal comes as Congress previously ignored similar cuts, opting instead to increase health spending.

Briefing: STAT+: Up and down the ladder: The latest comings and goings

Strategic angle: From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

Briefing: Biotech Investors Urge Trump Amid M&A Activity

Strategic angle: Smaller biotechs negotiate with the White House while addressing the trust gap in medicine.

Trump announces 100% tariffs on brand-name drugs, with plenty of carveouts

The taxes are part of the president's push to rein in the pharmaceutical industry and bring manufacturing to the U.S.

Briefing: Thursday was World Autism Awareness Day. HHS celebrated with…a workout?

Strategic angle: Implications of SCOTUS' conversion therapy ruling, Trump hikes drug tariffs, and more Morning Rounds updates

Briefing: Opinion: My patient would rather take a peptide than a statin. That reveals an uncomfortable truth in medicine

Strategic angle: “The volume of evidence behind a therapy has become inversely correlated with public trust in it,” writes Vikas Patel.

Briefing: Opinion: Subscription pricing could expand access to HIV prevention breakthrough while controlling costs

Strategic angle: Lenacapavir could put the end of the HIV epidemic in reach — if the people who need it can access it. Here’s one way to make that happen.

Briefing: Supreme Court conversion therapy decision could ripple through medicine

Strategic angle: A Supreme Court ruling this week on gender and sexuality 'conversion therapy' could narrow the authority of state medical boards over care involving speech.

Supreme Court rules against Colorado ban on ‘conversion therapy’ for LGBTQ kids

The Supreme Court's decision challenges state laws against a discredited practice aimed at LGBTQ+ youth.

Briefing: Medicare Advantage plans win extra $18.6 billion as feds cut star ratings measures

Strategic angle: CMS is scaling back the number of measures it uses to grade health insurers.

Briefing: Small Drugmakers Negotiate Pricing Deals Amid Tariff Threat

Strategic angle: The Trump administration is in talks with smaller pharmaceutical companies to establish new drug-pricing agreements.

Briefing: Biotech investors’ plea to Trump, and a busy M&A week

Strategic angle: How has the FDA's recent decisions on rare disease drugs affected investment trends? Why is Eli Lilly getting into sleep medicine?

Briefing: FDA’s Evolving View of What Makes a ‘Breakthrough’ Device

Strategic angle: An analysis of AI-powered devices that received the FDA's 'breakthrough' label.

Briefing: How health care could gum up Trump’s reconciliation push

Strategic angle: Cuts to health care spending might play a role in a complicated Congressional maneuver to fund immigration enforcement.

Briefing: Lilly’s obesity pill enters the oral GLP-1 game, Novo responds

Strategic angle: Potential import tariffs on drugs, Foundayo is here-o, and other biotech news from The Readout

Briefing: Trump Administration Plans 100% Tariff on Patented Medicines

Strategic angle: The FDA approves a new obesity pill from Lilly amidst tariff discussions.

Briefing: A Preview of the Role Health Care May Play in the 2026 Election

Strategic angle: Ahead of the 2026 midterm elections, this KFF issue brief examines the role health care has played in previous elections and its potential impact in 2026.

Briefing: Proposed ‘preclinical obesity’ diagnosis ignites global debate among experts

Strategic angle: A new way to define obesity aims to sharpen the diagnosis. Critics warn it could delay care, exclude diabetes, and deepen inequities in accessing treatment.